Legal & General Group Plc boosted its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,686 shares of the biopharmaceutical company’s stock after purchasing an additional 6,054 shares during the period. Legal & General Group Plc’s holdings in Horizon Pharma were worth $1,439,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. D.A. Davidson & CO. grew its stake in shares of Horizon Pharma by 5.1% during the fourth quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 512 shares in the last quarter. American International Group Inc. grew its stake in shares of Horizon Pharma by 0.8% during the fourth quarter. American International Group Inc. now owns 110,573 shares of the biopharmaceutical company’s stock valued at $2,161,000 after acquiring an additional 868 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Horizon Pharma by 10.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,271 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 1,149 shares in the last quarter. Private Capital Group LLC grew its stake in shares of Horizon Pharma by 141.5% during the fourth quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,150 shares in the last quarter. Finally, ETRADE Capital Management LLC grew its stake in shares of Horizon Pharma by 2.7% during the fourth quarter. ETRADE Capital Management LLC now owns 75,152 shares of the biopharmaceutical company’s stock valued at $1,468,000 after acquiring an additional 1,997 shares in the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.

Shares of HZNP stock opened at $24.92 on Monday. The company has a current ratio of 2.03, a quick ratio of 1.97 and a debt-to-equity ratio of 1.80. Horizon Pharma PLC has a one year low of $12.55 and a one year high of $29.44. The stock has a market cap of $4.60 billion, a PE ratio of 13.62, a P/E/G ratio of 1.42 and a beta of 1.14.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.54 by $0.13. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The business had revenue of $355.50 million for the quarter, compared to analysts’ expectations of $334.22 million. During the same quarter last year, the company posted $0.29 earnings per share. The company’s quarterly revenue was up 29.6% compared to the same quarter last year. As a group, analysts anticipate that Horizon Pharma PLC will post 1.7 EPS for the current year.

In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 8,835 shares of the firm’s stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the transaction, the executive vice president now owns 32,202 shares of the company’s stock, valued at $745,476.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Geoffrey M. Curtis sold 10,080 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $21.21, for a total transaction of $213,796.80. Following the completion of the transaction, the executive vice president now directly owns 35,367 shares in the company, valued at approximately $750,134.07. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

Several brokerages have recently weighed in on HZNP. Piper Jaffray Companies set a $33.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, April 4th. Jefferies Financial Group increased their price target on shares of Horizon Pharma to $34.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald increased their price target on shares of Horizon Pharma from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Zacks Investment Research raised shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 8th. Finally, Cowen set a $33.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. Horizon Pharma currently has an average rating of “Buy” and an average price target of $30.73.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/legal-general-group-plc-buys-6054-shares-of-horizon-pharma-plc-hznp/2980744.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Read More: Do Tariffs Work?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.